review · Health Science Reports
Repetitive transcranial magnetic stimulation is being investigated as a non-invasive neuromodulation therapy to address cognitive decline in people with mild to moderate Alzheimer's disease. A review of clinical trial evidence indicates that the technique can provide short-term improvements in cognitive performance and preliminary benefits for neuropsychiatric symptoms, alongside some indications of sustained effects during follow-up periods. The intervention is generally safe and well tolerated, with adverse events typically limited to mild or moderate transient headaches, scalp discomfort, localized pain, and fatigue. Nevertheless, significant variation across clinical studies regarding stimulation frequency, treatment duration, brain targets, and assessment measures prevents clear conclusions. Because existing studies feature small sample sizes, short follow-up durations, and risk of bias, routine clinical adoption is premature until larger, standardized trials are conducted.
Alzheimer's disease creates substantial burdens for patients and caregivers, driving the search for effective non-invasive therapies to slow cognitive decline. Clarifying the current clinical evidence for brain stimulation highlights its potential therapeutic value while helping healthcare providers, researchers, and funders understand the methodological gaps that must be solved before such treatments can be safely introduced into routine dementia management.
The therapeutic application targets clinical dementia care and neuromodulation device providers aiming to treat Alzheimer's disease. However, the technology remains at an early clinical research stage rather than near-market deployment. Widespread commercial adoption and clinical translation require resolving substantial protocol variations, establishing standardized treatment parameters, and validating efficacy through larger, sham-controlled clinical trials with long-term outcome measures.
AI-generated from the published abstract. Always read the original work before citing.
Background and Aims: Alzheimer's disease (AD), primarily characterized by cognitive impairment, places an immense burden on patients and caregivers. Non-invasive neuromodulation with repetitive transcranial magnetic stimulation has been proposed to improve cognition in mild to moderate AD. This narrative review aimed to summarize clinical trial evidence on the effects, safety, and tolerability of rTMS for AD-related cognitive impairment and to identify research gaps. Methods: A narrative review of clinical trials was performed. PubMed/MEDLINE, Embase, Cochrane Google scholar, and Scopus were searched from inception to January 25, 2025, using terms for "repetitive transcranial magnetic stimulation", "Alzheimer's disease", "cognitive impairment", "clinical trials", and "randomized controlled trial". Clinical trials of active rTMS versus sham or treatment-as-usual in adults with mild to moderate AD that reported validated cognitive outcomes were included. Data on rTMS protocols, cognitive measures, adverse effects, and follow-up were extracted and synthesized narratively without statistical pooling. Results: < 0.05], and some evidence of sustained benefit at follow-up. rTMS was generally safe and tolerable. Reported adverse effects were mild to moderate and included transient headache, scalp or skin discomfort, pain, and fatigue. Preliminary evidence also suggested potential neuropsychiatric benefits. However, substantial heterogeneity in duration, frequency, treatment plan, targets, and outcome measures limited definitive conclusions. Conclusion: rTMS appears safe in the short term and may be linked to short-term cognitive and neuropsychiatric gains in mild to moderate AD. However, marked protocol heterogeneity, small sample sizes, short follow-up, and risk of bias limit certainty and prevent identification of optimal parameters. rTMS is not ready for routine AD care. Larger, sham-controlled trials with standardized protocols and biomarker or long-term outcomes are needed.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1002/hsr2.73104
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
